MEDX vs OGN

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MEDX as a result. In 52 of 61 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for MEDX just turned positive on October 12, 2026. Looking at past instances where MEDX's MACD turned positive, the stock continued to rise in 26 of 32 cases over the following month. The odds of a continued upward trend are 81%.

MEDX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDX advanced for three days, in 181 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 162 of 189 cases where MEDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The 10-day RSI Indicator for MEDX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 54 cases where MEDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

MEDX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

OGN broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on OGN as a result. In 53 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for OGN just turned positive on October 29, 2026. Looking at past instances where OGN's MACD turned positive, the stock continued to rise in 22 of 35 cases over the following month. The odds of a continued upward trend are 63%.

Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in 180 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

The Aroon Indicator entered an Uptrend today. In 90 of 235 cases where OGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 38%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 40 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. OGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.621) is normal, around the industry mean (-1.421). P/E Ratio (17.557) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.006) settles around the average of (0.038) among similar stocks. OGN's P/S Ratio (0.589) is slightly lower than the industry average of (4.033).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.